Correction: 4-Aminopyridine treatment for nerve injury resulting from radical retro-pubic prostatectomy: a single-center double-blind, randomized, placebo-controlled study.

Ghazi, Ahmed; Osinski, Thomas L.; Feng, Changyong; Horne, Andrea; Elfar, John

This document is a correction notice for an article titled "4-Aminopyridine treatment for nerve injury resulting from radical retro-pubic prostatectomy: a single-center double-blind, randomized, placebo-controlled study." The original article can be found online at the provided link. The correction notice includes a disclosure statement from one of the authors, Dr. John Elfar, stating that he holds a patent on 4-aminopyridine and has invested in a startup company that intends to manufacture a pill alternative to the currently available generic pill used in the sponsored trials. Dr. Elfar served as the Chief Medical Officer at Solaxa until October 2023 and now only serves as a founder. The authors of the article are Ahmed Ghazi, Thomas L. Osinski, Changyong Feng, Andrea Horne, and John Elfar.

RADICAL prostatectomy; NERVOUS system injuries; NEW business enterprises; PILLS; PATENTS

Trials, 2024, Vol 25, Issue 1, p1

1745-6215

Academic Journal

10.1186/s13063-024-08518-7